Philip Furmanski
- Nutrition and Dietetics top 1%
- Infant Nutrition and Health 9
- Hematology top 5%
- Cancer Research top 5%
- Immunology top 5%
- Immune Cell Function and Interaction 9
- Virology top 5%
- HIV Research and Treatment 9
-
- Virus-based gene therapy research 18
-
- Erythrocyte Function and Pathophysiology 14
-
- Cancer Cells and Metastasis 8
-
- RNA Interference and Gene Delivery 7
-
- Monoclonal and Polyclonal Antibodies Research 7
- Co-authors
- Jianglin HeMartin LubinDavid J. SilvermanRamesh BhimaniCandace S. JohnsonClifford LongleyJohn F. MarcellettiMarvin A. Rich
- Partner nations
- United StatesSwitzerlandChina
In The Last Decade
Philip Furmanski
104 papers receiving 2.7k citations
Peers
Comparison fields: 5 of 123
- Nutrition and Dietetics 588
- Hematology 354
- Cancer Research 347
- Immunology 487
- Virology 108
Countries citing papers authored by Philip Furmanski
This map shows the geographic impact of Philip Furmanski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Furmanski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Furmanski more than expected).
Fields of papers citing papers by Philip Furmanski
This network shows the impact of papers produced by Philip Furmanski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Furmanski. The network helps show where Philip Furmanski may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Philip Furmanski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2020 | 13 | |
| 4 | 1999 | 93 | |
| 5 | Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer. | 1998 | 29 |
| 6 | 1998 | 12 | |
| 7 | 1995 | 6 | |
| 8 | 1995 | 308 | |
| 9 | 1994 | 5 | |
| 10 | 1993 | 26 | |
| 11 | 1993 | 7 | |
| 12 | 1992 | 2 | |
| 13 | In vivo effects of recombinant human and murine interleukin-1 alpha (IL-1 alpha) on murine hematopoiesis. | 1990 | 2 |
| 14 | 1989 | 106 | |
| 15 | 1987 | 102 | |
| 16 | Understanding breast cancer : clinical and laboratory concepts | 1983 | 14 |
| 17 | 1980 | 61 | |
| 18 | Concanavalin A-mediated hemadsorption by normal and malignant human mammary epithelial cells. | 1978 | 16 |
| 19 | Prognostic value of estrogen receptor determinations in patients with breast cancer. | 1978 | 88 |
| 20 | 1977 | 12 |
About Philip Furmanski
Philip Furmanski is a scholar working on Virology, Immunology and Oncology, having authored 106 papers that have together received 3.0k indexed citations. Recurring topics across this work include Virus-based gene therapy research (18 papers), Erythrocyte Function and Pathophysiology (14 papers), HIV Research and Treatment (9 papers), Immune Cell Function and Interaction (9 papers), Infant Nutrition and Health (9 papers), Cancer Cells and Metastasis (8 papers), RNA Interference and Gene Delivery (7 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). The work is most often cited by research in Nutrition and Dietetics (588 citations), Hematology (354 citations) and Cancer Research (347 citations). Philip Furmanski has collaborated with scholars based in United States, Switzerland and China. Frequent co-authors include Jianglin He, Martin Lubin, David J. Silverman, Ramesh Bhimani, Candace S. Johnson, Clifford Longley, John F. Marcelletti, Marvin A. Rich, Paul G. Braunschweiger and Wenhui Wan. Their work appears in journals such as Nature, Science and Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.